Oak Ridge Investments LLC lifted its holdings in shares of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) by 1.5% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 148,974 shares of the specialty pharmaceutical company’s stock after buying an additional 2,235 shares during the period. Oak Ridge Investments LLC’s holdings in Supernus Pharmaceuticals were worth $5,220,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the company. Menta Capital LLC raised its stake in shares of Supernus Pharmaceuticals by 3.5% during the 4th quarter. Menta Capital LLC now owns 7,824 shares of the specialty pharmaceutical company’s stock worth $260,000 after buying an additional 265 shares in the last quarter. Victory Capital Management Inc. raised its stake in shares of Supernus Pharmaceuticals by 4.1% during the 4th quarter. Victory Capital Management Inc. now owns 7,536 shares of the specialty pharmaceutical company’s stock worth $250,000 after buying an additional 296 shares in the last quarter. Advisor Group Inc. raised its stake in shares of Supernus Pharmaceuticals by 17.2% during the 4th quarter. Advisor Group Inc. now owns 2,082 shares of the specialty pharmaceutical company’s stock worth $69,000 after buying an additional 306 shares in the last quarter. Oregon Public Employees Retirement Fund raised its stake in shares of Supernus Pharmaceuticals by 1.8% during the 1st quarter. Oregon Public Employees Retirement Fund now owns 20,239 shares of the specialty pharmaceutical company’s stock worth $709,000 after buying an additional 366 shares in the last quarter. Finally, Campbell Newman Asset Management Inc. raised its stake in shares of Supernus Pharmaceuticals by 2.5% during the 1st quarter. Campbell Newman Asset Management Inc. now owns 16,567 shares of the specialty pharmaceutical company’s stock worth $581,000 after buying an additional 397 shares in the last quarter. 99.29% of the stock is owned by institutional investors and hedge funds.

In other Supernus Pharmaceuticals news, CFO Gregory S. Patrick sold 20,000 shares of the stock in a transaction on Wednesday, February 27th. The stock was sold at an average price of $41.53, for a total transaction of $830,600.00. Following the transaction, the chief financial officer now owns 67,896 shares of the company’s stock, valued at approximately $2,819,720.88. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 6.20% of the company’s stock.

A number of brokerages have recently issued reports on SUPN. Zacks Investment Research raised Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating and set a $46.00 target price for the company in a research note on Saturday, March 2nd. B. Riley set a $65.00 target price on Supernus Pharmaceuticals and gave the company a “buy” rating in a report on Monday, March 4th. Mizuho reiterated a “buy” rating and set a $63.00 target price on shares of Supernus Pharmaceuticals in a report on Wednesday, April 17th. ValuEngine cut Supernus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, March 6th. Finally, BidaskClub upgraded Supernus Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Thursday, April 4th. Three investment analysts have rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $56.13.

NASDAQ:SUPN traded up $0.73 during trading hours on Friday, reaching $33.60. 325,007 shares of the company traded hands, compared to its average volume of 579,288. The stock has a market cap of $1.76 billion, a PE ratio of 16.39, a price-to-earnings-growth ratio of 1.14 and a beta of 1.57. The company has a debt-to-equity ratio of 0.75, a quick ratio of 2.59 and a current ratio of 2.77. Supernus Pharmaceuticals Inc has a 1-year low of $30.05 and a 1-year high of $61.25.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings results on Tuesday, May 7th. The specialty pharmaceutical company reported $0.34 earnings per share for the quarter, missing analysts’ consensus estimates of $0.44 by ($0.10). Supernus Pharmaceuticals had a return on equity of 23.60% and a net margin of 25.49%. The business had revenue of $85.50 million for the quarter, compared to analysts’ expectations of $102.26 million. During the same period in the prior year, the company earned $0.49 EPS. The company’s revenue for the quarter was down 5.4% compared to the same quarter last year. As a group, equities research analysts predict that Supernus Pharmaceuticals Inc will post 2.24 earnings per share for the current fiscal year.

WARNING: This piece was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at https://www.watchlistnews.com/oak-ridge-investments-llc-has-5-22-million-stake-in-supernus-pharmaceuticals-inc-supn/3022034.html.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine.

Featured Story: What is diluted earnings per share (Diluted EPS)?

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals Inc (NASDAQ:SUPN).

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.